{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"331"},{"groupId":"OG001","spread":"23","value":"485"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"363"},{"groupId":"OG001","spread":"21","value":"536"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Includes participants from all treatment arms that were administered AMG 820 1100 mg.","id":"OG000","title":"AMG 820 1100 mg"},{"description":"Includes participants from all treatment arms who were administered AMG 820 1400 mg","id":"OG001","title":"AMG 820 1400 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacovigilence Analysis Set contains all participants who received at least 1 dose of AMG 820 and have at least one PK sample collected.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Study Day 1: pre-infusion, at end of infusion, hours 1, 6 and 24 post infusion, Days 5, 8 and 15. Cycle 2, Study Day 22: pre-infusion, at end of infusion, hours 1, 6, 24 post infusion, Days 26, 29 and 36","title":"AMG 820 Pharmacokinetic Parameter by Dose Group: Maximum Observed Drug Concentration (Cmax) During Treatment Cycles 1 + 2","type":"SECONDARY","unitOfMeasure":"ug/mL"}